Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Code Biotherapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Code Biotherapeutics's investors include New Enterprise Associates, Hatteras Venture Partners, 4BIO Capital, Amgen Ventures, UCB Ventures.
Code Biotherapeutics is headquartered in Hatfield, United States.
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Code Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Code Biotherapeutics — Funding & Investors." VCBacked, June 7, 2022, https://www.vcbacked.co/company/code-biotherapeutics. Accessed October 23, 2026.
VCBacked. (2022). Code Biotherapeutics — Funding & Investors. Retrieved October 23, 2026, from https://www.vcbacked.co/company/code-biotherapeutics
{{cite web |title=Code Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/code-biotherapeutics |website=VCBacked |access-date=October 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated